USD 255.29
(-2.5%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 89.14 Million USD | -30.87% |
2022 | 128.96 Million USD | 49.33% |
2021 | 86.36 Million USD | 14.84% |
2020 | 75.2 Million USD | 33.46% |
2019 | 56.34 Million USD | 134.12% |
2018 | 24.06 Million USD | 2406799900.0% |
2017 | 1.00 USD | 0.0% |
2016 | 1.00 USD | 0.0% |
2015 | 1.00 USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 1.00 USD | 0.0% |
2012 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 93.98 Million USD | 5.43% |
2024 Q3 | 75.98 Million USD | -9.52% |
2024 Q2 | 83.98 Million USD | -10.65% |
2023 Q4 | 89.14 Million USD | -6.92% |
2023 Q3 | 95.77 Million USD | -4.66% |
2023 Q2 | 100.45 Million USD | -23.83% |
2023 Q1 | 131.87 Million USD | 2.26% |
2023 FY | 89.14 Million USD | -30.87% |
2022 Q3 | 115.48 Million USD | 29.8% |
2022 Q2 | 88.97 Million USD | 13.32% |
2022 Q1 | 78.51 Million USD | -9.09% |
2022 FY | 128.96 Million USD | 49.33% |
2022 Q4 | 128.96 Million USD | 11.67% |
2021 Q3 | 97.89 Million USD | 16.05% |
2021 FY | 86.36 Million USD | 14.84% |
2021 Q4 | 86.36 Million USD | -11.78% |
2021 Q2 | 84.35 Million USD | 14.09% |
2021 Q1 | 73.94 Million USD | -1.68% |
2020 Q2 | 77.41 Million USD | 13.35% |
2020 Q4 | 75.2 Million USD | 12.34% |
2020 FY | 75.2 Million USD | 33.46% |
2020 Q1 | 68.3 Million USD | 21.21% |
2020 Q3 | 66.94 Million USD | -13.53% |
2019 Q3 | 54.56 Million USD | 34.43% |
2019 Q1 | 32 Million USD | 32.96% |
2019 FY | 56.34 Million USD | 134.12% |
2019 Q4 | 56.34 Million USD | 3.27% |
2019 Q2 | 40.58 Million USD | 26.83% |
2018 Q2 | 1.00 USD | 0.0% |
2018 Q1 | - USD | -100.0% |
2018 FY | 24.06 Million USD | 2406799900.0% |
2018 Q4 | 24.06 Million USD | 117.2% |
2018 Q3 | 11.08 Million USD | 1108099900.0% |
2017 FY | 1.00 USD | 0.0% |
2017 Q4 | 1.00 USD | 0.0% |
2017 Q3 | - USD | -100.0% |
2017 Q2 | 1.00 USD | 0.0% |
2017 Q1 | - USD | -100.0% |
2016 Q4 | 1.00 USD | 0.0% |
2016 FY | 1.00 USD | 0.0% |
2016 Q1 | - USD | -100.0% |
2016 Q2 | 1.00 USD | 0.0% |
2016 Q3 | 1.00 USD | 0.0% |
2015 Q4 | 1.00 USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | -100.0% |
2015 Q1 | 1.00 USD | 0.0% |
2015 FY | 1.00 USD | 0.0% |
2014 Q2 | - USD | -100.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q1 | 1.00 USD | 0.0% |
2014 FY | - USD | -100.0% |
2013 FY | 1.00 USD | 0.0% |
2013 Q2 | - USD | -100.0% |
2013 Q3 | 1.00 USD | 0.0% |
2013 Q4 | 1.00 USD | 0.0% |
2013 Q1 | 1.00 USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | -641.401% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -367.32% |
Amicus Therapeutics, Inc. | 59.69 Million USD | -49.333% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -818.463% |
bluebird bio, Inc. | 22.91 Million USD | -288.961% |
Cara Therapeutics, Inc. | 2.82 Million USD | -3060.085% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 76.897% |
Myriad Genetics, Inc. | 20.1 Million USD | -343.512% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -132.757% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -15.164% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 98.929% |
Waters Corporation | 516.23 Million USD | 82.732% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.248% |
Biogen Inc. | 2.52 Billion USD | 96.473% |
Nektar Therapeutics | 16.1 Million USD | -453.667% |
Perrigo Company plc | 1.14 Billion USD | 92.186% |
Dynavax Technologies Corporation | 53.29 Million USD | -67.285% |
Illumina, Inc. | 587 Million USD | 84.813% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -759.487% |
Heron Therapeutics, Inc. | 42.11 Million USD | -111.698% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 91.948% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -710.566% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 96.545% |
Esperion Therapeutics, Inc. | 65.62 Million USD | -35.846% |
FibroGen, Inc. | 41.56 Million USD | -114.474% |
Agilent Technologies, Inc. | 1.03 Billion USD | 91.353% |
OPKO Health, Inc. | 65.69 Million USD | -35.693% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Exelixis, Inc. | 17.32 Million USD | -414.611% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 96.523% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -489.006% |
Abeona Therapeutics Inc. | -2.44 Million USD | 3747.545% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 87.934% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -213.618% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 72.389% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -1053.247% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 30.137% |
Blueprint Medicines Corporation | 21.22 Million USD | -320.044% |
Insmed Incorporated | 83.24 Million USD | -7.085% |
TG Therapeutics, Inc. | 39.82 Million USD | -123.856% |
Incyte Corporation | 62.97 Million USD | -41.565% |
Emergent BioSolutions Inc. | 328.9 Million USD | 72.896% |